Financial calendar 2022 for FluoGuide, and release of the Q3 report 2021 is moved to 15[th] of November 2021
Copenhagen, Denmark, 5 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) releases financial calendar for 2022. The planned release of Q3 financial report 2021 is changed to 15th of November 2021
Financial calendar for 2022
|Year-end report 2021 and Annual report 2021||30 March 2022|
|Annual General Meeting||18 May 2022|
|Q1 2022 report||31 May 2022|
|Q2 2022 report||25 August 2022|
|Q3 2022 report||24 November 2022|
The planned release of the Q3 financial report 2021 is moved from 24th November to 15th November 2021.
For further information, please contact:
Henrik Moltke, CFO
+45 22 44 54 04
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.